Skip to main content
Premium Trial:

Request an Annual Quote

Danaher Forecasts 2012 Revenue Growth of 2 to 5 Percent

NEW YORK (GenomeWeb News) – Danaher today reaffirmed its fourth quarter guidance for 2011 and initiated its outlook for 2012.

The Washington, DC-based conglomerate, which acquired Beckman Coulter earlier this year for nearly $7 billion, reaffirmed that it expects its fourth-quarter adjusted earnings per share to be between $.75 and $.80.

It said that it expects its full-year 2012 EPS from continuing operations to be between $3.20 and $3.35 with core revenue growth from continuing operations of between 2 percent and 5 percent.

"We remain mindful that the recent macroeconomic headlines will likely make for a more challenging environment as we go forward," H. Lawrence Culp, president and CEO of Danaher, said in a statement.

The Scan

Time to Act

A new report urges the UK to consider regulations to protect against the misuse of genomic technologies, according to the Guardian.

Fulgent Seeking Defamation Suit

Fulgent Genetics says it plans to sue Los Angeles County Sheriff Alex Villanueva for defamation, the Los Angeles Times reports.

Speeding Gene-Edited Crops

Reuters reports that China's new trial rules will make it easier to grow gene-edited crops there.

Nucleic Acids Research Papers on Viral Recombination, Pan-Cancer Mutations, SARS-CoV-2 Variability

In Nucleic Acids Research this week: updated pipeline to detect viral recombination, mutational patterns in tumor samples, and more.